Clinical Trials

How Will Oruka Therapeutics Transform Chronic Skin Disease Treatment?
Management & Regulatory How Will Oruka Therapeutics Transform Chronic Skin Disease Treatment?

Chronic skin diseases like plaque psoriasis have long posed significant challenges for patients and medical professionals alike, with existing treatments often falling short in efficacy and patient compliance. However, the emergence of Oruka Therapeutics, Inc. is positioned to revolutionize the

Can Expanded Clinical Sites Enhance AL Amyloidosis Treatment Access?
Research & Development Can Expanded Clinical Sites Enhance AL Amyloidosis Treatment Access?

The advancement in biopharmaceutical research holds promise for patients with rare conditions such as relapsed/refractory AL amyloidosis. Immix Biopharma, Inc. (IMMIX), aims to tackle this debilitating disease through its innovative CAR-T cell therapy, NXC-201. As of August 28, 2024, the company

Immix Biopharma Expands NEXICART-2 Trial for AL Amyloidosis Treatment
Research & Development Immix Biopharma Expands NEXICART-2 Trial for AL Amyloidosis Treatment

Immix Biopharma, Inc. (Nasdaq: IMMX) recently announced a significant expansion of its clinical trial sites across the United States for the NEXICART-2 study, focusing on relapsed/refractory AL Amyloidosis. This expansion aims to provide broader patient access to innovative therapy options and

Are U.S. Clinical Trials in China Facing More FDA Scrutiny?
Research & Development Are U.S. Clinical Trials in China Facing More FDA Scrutiny?

U.S. lawmakers are raising alarms about clinical trials conducted in China, specifically those affiliated with the Chinese military or located in the Xinjiang Uyghur Autonomous Region. This heightened vigilance is poised to dramatically impact how the U.S. FDA scrutinizes data from these trials.

Cancer Drug Shows Promise in Protecting Mice from Alzheimer's Disease
Research & Development Cancer Drug Shows Promise in Protecting Mice from Alzheimer's Disease

Recent research breakthroughs have revealed an intriguing and unexpected benefit of certain cancer drugs: the potential to protect against Alzheimer's disease. Originally developed for combating cancer, these medications have shown promise in preventing Alzheimer's in animal models such

Regeneron’s Ordspono Wins EU Approval, Faces FDA Hurdle for Lymphoma
Research & Development Regeneron’s Ordspono Wins EU Approval, Faces FDA Hurdle for Lymphoma

The European Commission's recent authorization of Regeneron's bispecific antibody drug Ordspono (odronextamab) for the treatment of two types of lymphoma marks a significant milestone in the European market. Garnering approval for use across 27 European Union countries, Ordspono is now

Loading

Subscribe to our weekly news digest.

Join now and become a part of our fast-growing community.

Invalid Email Address
Thanks for Subscribing!
We'll be sending you our best soon!
Something went wrong, please try again later